Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Biotech dealmaking this week was lighter on blockbuster takeovers than earlier in 2026, but the tape was busy: Eli Lilly, Novo Nordisk, Novartis and AbbVie used licenses and research pacts to buy access to platforms rather than whole companies.Big pharma is still paying up, but more often for deliv…